Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16880151 | 0.95 | HDAC6 (0.48) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL16879891 | 0.92 | HDAC6 (0.43) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL16880158 | 0.92 | HDAC6 (0.48) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL16880078 | 0.92 | HDAC6 (0.50) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL16879874 | 0.91 | HDAC6 (0.51) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL16879919 | 0.90 | PTGER4 (0.41) | HDAC6HDAC1 | |
| SCHEMBL16880093 | 0.89 | HDAC1 (0.52) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL16880016 | 0.89 | HDAC6 (0.43) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL16880247 | 0.88 | HDAC6 (0.42) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL16880056 | 0.88 | HDAC6 (0.43) | HDAC6HDAC1HDAC8HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-12-08 | — | — | US | claimed |
| EP-3089977-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-11-09 | — | — | EP | claimed |
| WO-2015102426-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-07-09 | — | — | WO | claimed |
| US-20220401474-A1 | HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF | MEDSTAR HEALTH | 2022-12-22 | — | — | US | disclosed |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-12-08 | — | — | US | disclosed |
| EP-3089977-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-11-09 | — | — | EP | disclosed |
| CN-106029655-A | Novel indole derivative compound and pharmaceutical composition comprising the same | 株式会社钟根堂 | 2016-10-12 | — | — | CN | disclosed |
| WO-2015102426-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401474-A1 | HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC8 6/4885 |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC2, HDAC1, HDAC3 | HDAC6 4/4885HDAC1 2/4885HDAC8 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.